Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06076980
Other study ID # paracetamol in septic shock
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 1, 2020
Est. completion date January 24, 2023

Study information

Verified date October 2023
Source Al-Azhar University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock is defined as sepsis that has circulatory, cellular, and metabolic abnormalities that are associated with a greater risk of mortality than sepsis alone. Clinically, this includes patients who fulfill the criteria for sepsis who, despite adequate fluid resuscitation, require vasopressors to maintain a mean arterial pressure ≥65 mmHg and have a lactate >2 mmol/L (>18 mg/dL). Feve is a common sign of infection in septic shock critically ill patients. Many critically ill patients experience pain. Paracetamol is considered safe and currently one of the most common antipyretics and used as part of multimodal analgesia for acute pain in the intensive care unit. According to the company's product information leaflet, the rate of hypotension complicating intravenous paracetamol treatment ranges from 0.01 to 0.1%. However, recent studies reported a much higher incidence and may be harmful in critically ill adults. The hemodynamic effects of intravenous (IV) paracetamol are unknown in septic shock patients, that the most vulnerable population and hemodynamically unstable. The aim of this study is to assess the incidence of hypotension of the extended intravenous paracetamol (acetaminophen) infusion over three hours in comparing with intravenous paracetamol bolus over 15 minutes in hemodynamically unstable patients (septic shock).


Description:

Sepsis, inflammatory response to infection, contributes directly or indirectly to mortality in the majority of critically ill patients. An elevated cardiac index and a decreased systemic vascular resistance leading to hypotension and hypoperfusion of vital organs characterize the early stage of septic shock. The hypotensive state is often not amenable to fluid resuscitation alone and requires institution of vasoactive agents to counter the profound fall in systemic vascular resistance, which is an integral feature of septic shock . Acetaminophen is the antipyretic and analgesic that is most often given to hospitalized patients, including those in critical care units. The mechanism of action of acetaminophen remains incompletely understood, but the antipyretic response appears to be due to blocking cyclooxygenase-II and inhibiting prostaglandin-II synthesis in the central nervous system. Intravenous (IV) acetaminophen has gained popularity for inpatient management of acute pain for its practical and clinical advantages. IV administration is associated with more predictable pharmacokinetic performance compared with rectal (30%-40% bioavailability) and oral dosage forms of acetaminophen (60%-70% bioavailability). Predictable kinetics as well as ease of IV administration has made it an especially attractive option in the critically ill patients who have altered gut absorption secondary to numerous pathophysiological and therapeutic influences . IV acetaminophen has shown promise in improving patient satisfaction, managing fever, and decreasing postoperative opioid requirements. These features have made it one of the most widely ordered medications within critical care and surgical services. Product information for IV acetaminophen lists mild effects such as nausea or vomiting among the most common adverse events (incidence ≥ 5%), with the estimated incidence of more serious adverse effects such as hypotension being <1%. However, there have been an increasing number of randomized controlled trials which indicated that the incidence of IV acetaminophen-induced hypotension may be higher than previously reported by manufacturers. These publications have prompted investigators to look more closely at the possible untoward effects of IV acetaminophen across a variety of populations. . None of these studies examined whether the extended infusion of IV paracetamol can minimize the degree of hypotension in critically heamodynamic unstable patients.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date January 24, 2023
Est. primary completion date November 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age adult = 18 years old. 2. The patient fulfills the criteria of septic shock definition: - Sepsis needs vasopressor therapy. - Serum lactate level greater than 2 mmol/l (SSC 2016). 3. Patient with contractility greater than 40% Exclusion Criteria: 1. paracetamol hypersensitivity or allergy. 2. Acute liver injury or failure 3. Childs-Pugh C liver disease 4. Heat stroke. 5. Malignant hyperthermia. 6. Neuroleptic Malignant Syndrome. 7. Continous renal replacement therapy. 8. Ventricular assist device. 9. Around-the-clock scheduled of acetaminophen-containing medications administration or non-steroidal anti-inflammatory drugs. 10. Pregnancy/lactation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Paracetamol
compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
Normal saline
as placebo

Locations

Country Name City State
Egypt Cairo University hospitals Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ayah Mohammed Khalil

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Maxwell EN, Johnson B, Cammilleri J, Ferreira JA. Intravenous Acetaminophen-Induced Hypotension: A Review of the Current Literature. Ann Pharmacother. 2019 Oct;53(10):1033-1041. doi: 10.1177/1060028019849716. Epub 2019 May 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of hypotension . defined as a decrease in SBP = 20% from baseline, by extended infusion of intravenous paracetamol pre intervention and six hours after the intervantion
Secondary The changes in hemodynamic parameters Changes in mean arterial pressure(mmHg), diastolic blood pressure (mmHg) pre intervention and six hours after the intervantion
Secondary The changes in hemodynamic parameters Changes in cardiac output ( L/min) pre intervention and six hours after the intervantion
Secondary The changes in hemodynamic parameters Changes in heart rate (bpm) pre intervention and six hours after the intervantion
Secondary The changes in hemodynamic parameters Changes in central venous pressure (mmHg) pre intervention and six hours after the intervantion
Secondary The changes in temperature Changes in temperature (celsius) pre intervention and six hours after the intervantion
Secondary The changes in vassopresors and fluid bolus changes in vassopresors infusion rate (mcg/ min) and fluid bolus pre intervention and six hours after the intervantion
Secondary The changes in vassopresors and fluid bolus changes in fluid bolus (ml) pre intervention and six hours after the intervantion
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3